Finance

Lists
NOVA:FRA
Novo Nordisk A/S
40,26 €
-9,16%
(-4,06) 1D
31 шіл., 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for NOVA...
Open
44,94 €
High
44,94 €
Low
40,00 €
Mkt. cap
159,35 млрд
Avg. vol.
1,81 мың
Volume
0,00
52-wk high
54,80 €
52-wk low
30,45 €
No. of employees
68 мың
Open
44,94 €
High
44,94 €
Low
40,00 €
Mkt. cap
159,35 млрд
Avg. vol.
1,81 мың
Volume
0,00
52-wk high
54,80 €
52-wk low
30,45 €
No. of employees
68 мың
News stories
From sources across the web
Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees67,9 мың
Founded1923 ж. 21 жел.
HeadquartersBagsværd, Астаналық облыс, Дания
SectorPharmaceutical industry
Websitenovonordisk.com
Previous reportsAll values in DKK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in DKK
2025 ж. мау.
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
Revenue
76,86 млрд
74,98 млрд
79,14 млрд
96,82 млрд
Cost of goods sold
12,85 млрд
14,47 млрд
14,17 млрд
13,60 млрд
Cost of revenue
12,85 млрд
14,47 млрд
14,17 млрд
13,60 млрд
Research and development expenses
11,69 млрд
11,49 млрд
12,67 млрд
10,28 млрд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
18,85 млрд
15,76 млрд
17,14 млрд
13,22 млрд
Operating expense
30,56 млрд
27,25 млрд
29,73 млрд
23,61 млрд
Total operating expenses
43,41 млрд
41,72 млрд
43,90 млрд
37,20 млрд
Operating income
33,45 млрд
33,25 млрд
35,24 млрд
59,62 млрд
Other non operating income
-
1,53 млрд
-241,00 млн
-
EBT including unusual items
33,80 млрд
25,52 млрд
34,18 млрд
62,17 млрд
EBT excluding unusual items
33,80 млрд
35,09 млрд
37,62 млрд
62,17 млрд
Income tax expense
7,30 млрд
5,51 млрд
7,29 млрд
13,62 млрд
Effective tax rate
21,60%
21,60%
21,34%
21,90%
Other operating expenses
23,00 млн
-
-81,00 млн
106,00 млн
Net income
26,50 млрд
20,01 млрд
26,89 млрд
48,56 млрд
Net profit margin
34,48%
26,68%
33,98%
50,15%
Earnings per share
5,96
4,50
6,04
6,63
Interest and investment income
5,31 млрд
307,00 млн
4,41 млрд
-
Interest expense
-4,96 млрд
-
-4,97 млрд
-
Net interest expenses
356,00 млн
307,00 млн
-560,00 млн
-
Depreciation and amortization charges
-
-
-
-
EBITDA
37,65 млрд
36,49 млрд
36,66 млрд
63,13 млрд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google қолданбалары